IDO1抑制剂在实体肿瘤治疗中的研究进展

Research progress of indoleamine 2,3-dioxygenase 1 inhibitors in solid tumor therapy

肿瘤发生与免疫逃逸密切相关,免疫治疗已成为重要的肿瘤治疗方法之一。吲哚胺-2,3-双加氧酶1(indoleamine 2,3-dioxygenase 1,IDO1)在肿瘤微环境中的肿瘤细胞和抗原递呈细胞上过表达,IDO1激活促进色氨酸分解产生犬尿氨酸,后者诱导T细胞耗竭,因此有望成为一种新的免疫治疗靶点。IDO1抑制剂逐渐进入肿瘤临床应用,它不仅作为肿瘤免疫调节剂,也可联合免疫治疗和化学治疗。目前,已有数种IDO1抑制剂进入各期临床试验,本文系统综述IDO1抑制剂在实体肿瘤治疗中的研究进展。

Tumorigenesis is closely related to immune escape,and immunotherapy has become one of the important methods of tumor treatment.Indoleamine 2,3-dioxygenase 1(IDO1) is overexpressed in tumor cells and antigen presenting cells in tumor microenvironment.IDO1 is expected to be a new immunotherapeutic target as it promotes the decomposition of tryptophan to produce kynurenine,which induces T cell depletion.IDO1 inhibitors gradually enter the clinical application of tumors,they may leverage not only immuno-oncology modalities but also immunotherapy and chemotherapy.At present,several IDO1 inhibitors have been used in clinical trials of antitumor therapy at different stages.This article reviews the research progress of IDO1 inhibitors in clinical trials of solid tumors.